Physician profile
Daniel Welchons
NPI 1568786366
$187,094.75
in general payments reported to CMS, 2019-2025
48 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $2,108 · 2021: $1,328 · 2022: $1,987 · 2023: $32K · 2024: $69K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Consulting Fee: $40K · Travel and Lodging: $11K · Food and Beverage: $9,110 · Honoraria: $1,575 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,081.25 |
| Consulting Fee | $39,822.50 |
| Travel and Lodging | $10,744.93 |
| Food and Beverage | $9,109.95 |
| Honoraria | $1,575.00 |
| Education | $186.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $141,861.83 | 2021-2025 | Barrigel, Urolift |
| Palette Life Sciences, INC. | $28,027.94 | 2022-2023 | |
| Bioprotect Medical, INC. | $4,612.30 | 2024-2025 | Bioprotect Balloon Implant System |
| Dendreon Pharmaceuticals LLC | $2,084.87 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $1,546.51 | 2020-2023 | Prolaris, Myrisk |
| Janssen Biotech, INC. | $1,028.18 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $1,011.21 | 2019-2025 | Xtandi, Myrbetriq |
| Medtronic, INC. | $666.49 | 2021-2025 | Interstim, Altaviva, Nuro |
| Abbvie INC. | $658.61 | 2019-2025 | Botox |
| Axonics, INC. | $515.54 | 2021-2024 | Bulkamid, Axonics |
| Merck Sharp & Dohme LLC | $482.58 | 2020-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $379.24 | 2020-2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $334.34 | 2019-2025 | |
| Pfizer INC. | $295.69 | 2019-2025 | |
| Neotract INC. | $258.10 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Welchons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.